LX-6171
CAS No. 914808-66-5
LX-6171( —— )
Catalog No. M34323 CAS No. 914808-66-5
LX-6171, a proline transporter (SLC6A7) inhibitor, is used potentially for the treatment of schizophrenia and Alzheimer's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 217 | Get Quote |
|
| 5MG | 342 | Get Quote |
|
| 10MG | 504 | Get Quote |
|
| 25MG | 790 | Get Quote |
|
| 50MG | 1086 | Get Quote |
|
| 100MG | 1431 | Get Quote |
|
| 500MG | 2871 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLX-6171
-
NoteResearch use only, not for human use.
-
Brief DescriptionLX-6171, a proline transporter (SLC6A7) inhibitor, is used potentially for the treatment of schizophrenia and Alzheimer's disease.
-
DescriptionLX-6171, a proline transporter (SLC6A7) inhibitor, is used potentially for the treatment of schizophrenia and Alzheimer's disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number914808-66-5
-
Formula Weight377.87
-
Molecular FormulaC22H20ClN3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESClC=1C=C(C2=CC=C(C(=O)C3CCN(CC3)C=4N=CC=CN4)C=C2)C=CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
N'-Methylnicotinamid...
N-methylnicotinamide is a metabolite of niacin (or nicotinamide) and is commonly found in human urine. However low levels of urinary excretion of N-methylnicotinamide indicates niacin deficiency. In patients with liver cirrhosis nicotinamide methylation is increased leading to a rise in urinary N-methylnicotinamide. N-methylnicotinamide has been found to be a microbial metabolite.
-
HARMANE
Harmane (harman) is a bio-active β-Carboline and monoamine oxidase inhibitor found in coffee and tobacco smoke.
-
HET0016
HET0016 is a potent and selective 20-HETE synthase inhibitor (IC50s: 17.7 nM, 12.1 nM, and 20.6 nM for recombinant CYP4A1-, CYP4A2-, and CYP4A3-catalyzed 20-HETE synthesis) and a selective CYP450 inhibitor, shown to inhibit angiogenesis and tumor growth.
Cart
sales@molnova.com